Medical Condition News

RSS

Best P.A.D. Research Awards honor investigators for research on peripheral arterial disease

The Peripheral Arterial Disease (P.A.D.) Coalition presented the Coalition's second annual Best P.A.D. Research Awards to the top three research papers on P.A.D. published in 2009 at the organization's Seventh Annual Meeting in Alexandria, VA last week. The Best P.A.D. Research Awards honor the work of investigators and acknowledge the creation of new clinical research relevant to the understanding and/or treatment of peripheral arterial disease.

30 Sep 2010

Cardium expands wound healing and tissue regeneration portfolio

Cardium Therapeutics announced that it has gained exclusive access to commercial development rights for certain novel supramacromolecular polymer complexes enabling regulatable and localized topical delivery of nitric oxide for prolonged periods of one to three weeks, to broaden and expand the Company's wound healing and tissue regeneration portfolio.

30 Sep 2010

Tengion presents Neo-Kidney Augment development program at ISCT Symposium

Tengion, Inc. presented new research data yesterday in a podium presentation at the 2nd Annual Symposium on Stem Cell Translation of the International Society for Cellular Therapy (ISCT) in San Francisco. The presentation highlighted new results from Tengion's Neo-Kidney Augment development program demonstrating success with an autologous cellular therapy approach to kidney regeneration in a rodent model of obesity, diabetes and hypertension.

30 Sep 2010

PAF launches new Colorectal Financial Aid Fund

The Patient Advocate Foundation (PAF) a national non-profit resolving patient access to health care issues, medical financial limitations, insurance denials and multiple government program enrollments, including Medicaid and Social Security Disability Income announced today that it launched a new Colorectal Financial Aid Fund (FAF) beginning September 28, 2010.

30 Sep 2010

Tryton reports positive interim results from Side Branch Stent System study

Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, announced interim six-month results from a symposium during the Transcatheter Cardiovascular Therapeutics (TCT) 2010 conference in Washington, D.C.

30 Sep 2010

Multi-disciplinary approach increases breast cancer survival rate: Study

Advances in screening for disease detection, better surgical techniques available to more women, and an increased number of therapies that reduce the risk of relapse in patients with both locally advanced and early stage disease, have collectively contributed to dramatic improvements in breast cancer's survival rates, according to a review of 60 years of patient records at The University of Texas MD Anderson Cancer Center.

30 Sep 2010

Penn Medicine selected as study site for PPMI

The Penn Medicine Parkinson's Disease and Movement Disorders Center announced that it is one of 18 official study sites for the Parkinson's Progression Markers Initiative (PPMI), a landmark observational clinical study sponsored by The Michael J. Fox Foundation, which will use a combination of advanced imaging, biologics sampling and behavioral assessments to identify biomarkers of Parkinson's disease progression.

30 Sep 2010

New online CDSMP program launched to battle against chronic illnesses

Taking the battle against the national epidemic of chronic illnesses to the Internet, the National Council on Aging (NCOA) is making Better Choices, Better Health, the online version of the internationally recognized Chronic Disease Self Management Program (CDSMP), available free for people in California and six other states Hawaii, Iowa, Maine, Massachusetts, New Jersey, and Oregon.

30 Sep 2010

Study suggests drugs targeting glutamatergic transmission may help treat psychotic illness

There is growing evidence that two neurotransmitters dopamine and glutamate are abnormal in people with psychotic illness, including schizophrenia. Among many other things, these chemicals play a role in cognitive functions, such as memory, learning, and problem solving.

30 Sep 2010

American Brain Tumor Association awards $100,000 clinical research grant

The Section on Tumors of the American Association of Neurological Surgeons and Congress of Neurological Surgeons has announced a $100,000 two-year ($50,000/year) clinical research grant funded by the American Brain Tumor Association (ABTA). The application is open exclusively to neurosurgeons who are members of the AANS/CNS Section on Tumors.

30 Sep 2010

Study shows tobacco control program reduces lung cancer rate

A study led by researchers at the University of California, San Diego shows that California's 40 year-long tobacco control program has resulted in lung cancer rates that are nearly 25 percent lower than other states.

30 Sep 2010

Study shows immunotherapy improves survival rate in children with neuroblastoma

Using immunotherapy biologic agents that stimulate the body's immune system pediatric oncologists have achieved the first substantial increase in over a decade in cure rates for the childhood cancer neuroblastoma. A newly released study shows that the new treatment improved two-year survival rates by 20 percent, compared to standard treatment for an aggressive form of neuroblastoma, a cancer of the nervous system.

30 Sep 2010

AccuPSA test for detecting prostate cancer recurrence

A new test could reliably detect early increases in prostate specific antigen (PSA) levels a biomarker commonly used to measure the recurrence of prostate cancer in men who have undergone prostate cancer treating surgery. Earlier detection of these rising levels would allow men with cancer recurrence to undergo earlier, more effective treatment for potentially better outcomes.

30 Sep 2010

Dyax, CMIC enter agreement to develop and commercialize DX-88 for HAE treatment

Dyax Corp. and CMIC Co., Ltd, announced today an agreement to develop and commercialize subcutaneous DX-88 (ecallantide) for the treatment of hereditary angioedema (HAE) and other angioedema indications in Japan.

30 Sep 2010

Mount Sinai receives contract to develop nanotechnology tools for diagnosing diseases

Mount Sinai School of Medicine received a contract for almost $16.5 million from The National Institutes of Health (NIH) and the National Heart and Lung Institute (NHLBI) through the Program of Excellence in Nanotechnology (PEN). The contract is one of four issued nationally to develop multidisciplinary research Centers with the goal of developing nanotechnology tools for diagnosing and treating heart, lung and blood diseases.

30 Sep 2010

New miRNA screening assay to detect early-stage colorectal cancer

A new microRNA (miRNA) screening assay detected the majority of early-stage colorectal cancers with good specificity and sensitivity. Our test has the potential to be safe, cheap, robust, accurate and of little or no inconvenience to the individual, and could, therefore, easily be integrated into national screening programs as part of an annual checkup,said Søren Jensby Nielsen, Ph.D., scientific manager, Diagnostic Product Development, Exiqon A/S

30 Sep 2010

Researchers explain why obesity is resistant to treatment

New research provides evidence of the vicious cycle created when an obese individual overeats to compensate for reduced pleasure from food.Obese individuals have fewer pleasure receptors and overeat to compensate, according to a study by University of Texas at Austin senior research fellow and Oregon Research Institute senior scientist Eric Stice and his colleagues published this week in The Journal of Neuroscience.

30 Sep 2010

NIH awards three grants to explore novel treatment strategies for muscular dystrophy

Three grants totaling more than $4.5 million, from agencies of the National Institutes of Health, will be used to explore novel treatment strategies for muscular dystrophy.

30 Sep 2010

Triple negative breast cancer patients with BRCA gene mutations have low risk of recurrence: Research

Patients with triple negative breast cancer that also have mutations in the BRCA gene appear to have a lower risk of recurrence, compared to those with the same disease without the deleterious genetic mutation, according to researchers at The University of Texas MD Anderson Cancer Center.

30 Sep 2010

MicroRNAs assay may allow better targeted therapy for lung cancer patients

A test based on a panel of microRNAs under development by Rosetta Genomics, Ltd., in Rehovot, Israel, may allow for more precise diagnosis and better targeted therapy for patients with lung cancer.

30 Sep 2010